A Texas company is licensing intellectual property from the University of Pittsburgh that will be used to develop gene therapy treatments for diabetes.
Austin, Texas-based Genprex Inc., a publicly traded clinical stage gene therapy company, signed an exclusive licensing agreement for technology that will allow two genes related to the production of glucose to be administered directly into the pancreas. The technology was developed in the lab of George Gittes, chief of the Division of Pediatric Surgery at Pitt’s School of Medicine.
Genprex licensed a related technology from Pitt earlier this year.
“In licensing this latest exclusive technology, which joins several others that provide us with multiple diabetes gene therapy combinations, we have valuable rights over what we believe are the most innovative, emerging diabetes gene therapies,” Genprex Chairman and CEO Rodney Varner said in a prepared statement.
Genprex was founded in 2009 and began trading publicly in 2018. The company, which is also developing gene therapy for the treatment of cancer, has two drug candidates for diabetes, which the company says have the potential to stabilize glucose levels and reduce insulin requirements.
Kris B. Mamula: kmamula@post-gazette.com




Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.